月別アーカイブ: 2013年10月

Nutra Pharma Announces Launch of Equine Nyloxin(R) for Use in Horses

CORAL SPRINGS, FL–(Marketwired – Oct 30, 2013) – Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they are in the process of launching the newest addition to their line of homeopathic treatments for chronic pain, Equine Nyloxin®.

Equine Nyloxin® is a topical therapy for horses that is packaged as a two piece kit: Nyloxin® Topical Gel comprises Step 1 and a solution of DMSO (dimethylsulfoxide) comprises Step 2. Specialized proteins in Nyloxin® block the action of acetylcholine, a major stimulating neurotransmitter in the nervous system and activator of the inflammatory pathways. As a result, the pain and inflammation pathways are temporarily shut off. DMSO has long been used topically in horses to reduce swelling and inflammation associated with strained muscles and soft tissue injuries. The DMSO also greatly enhances the uptake of the Nyloxin peptides into the joints.

“We’ve been using Nyloxin with horses for a few years with great results,” commented Rik J Deitsch, CEO of Nutra Pharma Corporation. “Recently we were approached by horse trainers that requested a product specifically formulated for use with equines. Since DMSO is already accepted and utilized by many trainers, it was easy to create this new approach to marry a DMSO gel formulation with our Nyloxin Topical Gel,” he continued. “We’ve been working with trainers and veterinarians in the equine industry and have already identified distributors for the Equine Nyloxin®,” he concluded.

According to The America Horse Council Foundation, there are over 9.2 million horses in the United States with more than 2 million people that own horses. The horse industry has a direct economic effect on the U.S. of $39 billion annually. Additionally, there are horses in every state and Forty-five states have at least 20,000 horses each.

Recently, Nutra Pharma announced the launch of Pet Pain-Away, an oral formulation for the treatment of moderate to severe chronic pain in companion animals. The Equine Nyloxin® represents the Company’s first topical solution for the animal market. Nutra Pharma expects to have the product available in the first quarter of 2014.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit: www.NutraPharma.com or www.Nyloxin.com

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The launch of Equine Nyloxin should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its present or future financial condition. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Source Article from http://finance.yahoo.com/news/nutra-pharma-announces-launch-equine-120000715.html
Nutra Pharma Announces Launch of Equine Nyloxin(R) for Use in Horses
http://finance.yahoo.com/news/nutra-pharma-announces-launch-equine-120000715.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results



Research and Markets: Global Pharmacy Automation Systems Market Report 2013- 2018

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/qvr8kt/pharmacy)
has announced the addition of the “Global
Pharmacy Automation Systems Market Report 2013- 2018″
report to
their offering.

This research analysis provides details of the several pharmacy
automation devices currently available in the market along with the
impact of these machines on modern pharmacies in terms of efficiency,
reduction in error and speed. The report also highlights the unique
connection of pharmacy automation devices with a number of other markets
such as the E-prescription market and its role in the growth of pharmacy
automation.

The scope of the report includes competitive analysis of major market
segments based on end users, technology and of different regional
markets such as Europe, North America, Asia-Pacific and the rest of the
world. This regional analysis concluded that most developing regions are
not yet ready to accept pharmacy automation technology since affordable
human skill and low currency value still provides a cheaper work force
as compared to mechanization. Along with this, the cost of devices and
setting them up is predicted to be another factor holding back the
growth of the market. A Porter’s Five Forces analysis provides insight
into industry competition and market dynamics.

Key Topics Covered:

1 Preface

2 Executive summary

3 Pharmacy automation market analysis

3.1 Current market trends and future outlook

3.2 Role of IT applications in pharmacy automation

3.3 Trends of IT applications in pharmacy automation

3.4 Market drivers

3.5 Market restraints

3.6 Market opportunities

3.7 Market attractiveness

3.8 Porters five forces analysis for pharmacy automation technologies

4 Pharmacy automation market analysis by application, 2012 – 2018

4.1 Market overview

5 Pharmacy automation market analysis, by end users, 2012 – 2018

5.1 Market overview

6 Pharmacy automation market analysis, by geography, 2012 – 2018

6.1 Market overview

7 Key competitors analysis

8 Company profile analysis

Companies Mentioned

  • AmerisourceBergen Corporation
  • Baxter International Inc.
  • CareFusion Corporation
  • Cerner Corporation
  • Health Robotics SRL
  • Kirby Lester
  • McKesson Corporation
  • Omnicell Inc
  • ScriptPro LLC
  • Swisslog Holding Ltd
  • Talyst Inc
  • Yuyama Co., Ltd

For more information visit http://www.researchandmarkets.com/research/qvr8kt/pharmacy

Source Article from http://finance.yahoo.com/news/research-markets-global-pharmacy-automation-111700467.html
Research and Markets: Global Pharmacy Automation Systems Market Report 2013- 2018
http://finance.yahoo.com/news/research-markets-global-pharmacy-automation-111700467.html
http://news.search.yahoo.com/news/rss?p=pharmacy
pharmacy – Yahoo News Search Results
pharmacy – Yahoo News Search Results





Axxess Pharma Inc. Receives Signed Term Sheet From TCA Global Credit Master Fund to Secure US $4 Million Revolving …

TORONTO, ON–(Marketwired – Oct 30, 2013) – Axxess Pharma Inc. (PINKSHEETS: AXXE) a specialty pharmaceutical and nutritional supplements company is pleased to announce they have received a signed term sheet from TCA Global Credit Masters Fund (TCA) to secure a US $4 million revolving line of credit. Closing is anticipated within 14 days, pending final due diligence from Axxess Pharma Inc. and TCA. The revolving line of credit will enable Axxess Pharma to generate significant revenue in the near-term with high gross profit margins.

This is expected to be the beginning of a long-term partnership between TCA Global and Axxess Pharma which will assist Axxess Pharma’s capital needs as sales continue to grow. The line of credit will be used to aggressively develop, market and sell its line of pain relief and muscle recovery products worldwide, as well as develop and market a vitamins and minerals line under the TapouT brand name. Management will also release a second wave of TapouT branded products which will be a premium vitamins line.

“This is an exciting time for our company. The $4 million revolving line of credit with TCA will allow our company to expand worldwide, fulfil current orders and quickly become a multi-million dollar revenue generating company,” said Dr. Bagi, President of Axxess Pharma Inc.” Dr. Bagi further stated, “In addition to our current TapouT products, we have additional products in the pipeline for release in 2014.”

About TCA Fund Management Group:

TCA Fund Management Group (www.trafcap.com) as the Investment Manager for TCA Global Credit Master Fund L.P. acts as an advisor to many small companies from its offices in the United States, United Kingdom, and Australia. TCA is a short duration, absolute return fund specializing in senior-secured lending to small, mainly listed companies in the U.S., Canada, Western Europe, and Australia. The team has a level of domestic and cross-border expertise, long-standing experience with funding innovations, as is reflected in the number of transactions completed. This is a specialist business with an investment approach that fills an important finance gap in many leading markets. TCA provides a unique conduit for investors seeking uncorrelated returns in the small cap debt universe.

About Axxess Pharma Inc.:

Axxess Pharma Inc. is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary: Axxess Pharma Canada Inc., headquartered in Toronto. Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess’s goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, to optimal health management through improved nutritional supplements.

For more information, please visit www.axxesspharmainc.com, or contact Investor Relations at (973) 351-3868.

Safe Harbor Statement

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

Source Article from http://finance.yahoo.com/news/axxess-pharma-inc-receives-signed-110000690.html
Axxess Pharma Inc. Receives Signed Term Sheet From TCA Global Credit Master Fund to Secure US $4 Million Revolving …
http://finance.yahoo.com/news/axxess-pharma-inc-receives-signed-110000690.html
http://news.search.yahoo.com/news/rss?p=pharma
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results